Energy as a Service Market (By Application: Rare Genetic Diseases, Oncology, Respiratory Diseases, Infectious Diseases, Others; By Type: Prophylactic Vaccines, Therapeutic Vaccines, Therapeutic Drugs; By End User: Hospitals & Clinics, Research Organizations, Other) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on MRNA Therapeutics Market 

5.1. COVID-19 Landscape: MRNA Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global MRNA Therapeutics Market, By Application

8.1. MRNA Therapeutics Market, by Application, 2023-2032

8.1.1 Rare Genetic Diseases

8.1.1.1. Market Revenue and Forecast (2021-2032)

8.1.2. Oncology

8.1.2.1. Market Revenue and Forecast (2021-2032)

8.1.3. Respiratory Diseases

8.1.3.1. Market Revenue and Forecast (2021-2032)

8.1.4. Infectious Diseases

8.1.4.1. Market Revenue and Forecast (2021-2032)

8.1.5. Others

8.1.5.1. Market Revenue and Forecast (2021-2032)

Chapter 9. Global MRNA Therapeutics Market, By Type

9.1. MRNA Therapeutics Market, by Type, 2023-2032

9.1.1. Prophylactic Vaccines

9.1.1.1. Market Revenue and Forecast (2021-2032)

9.1.2. Therapeutic Vaccines

9.1.2.1. Market Revenue and Forecast (2021-2032)

9.1.3. Therapeutic Drugs

9.1.3.1. Market Revenue and Forecast (2021-2032)

Chapter 10. Global MRNA Therapeutics Market, By End User 

10.1. MRNA Therapeutics Market, by End User, 2023-2032

10.1.1. Hospitals & Clinics

10.1.1.1. Market Revenue and Forecast (2021-2032)

10.1.2. Research Organizations

10.1.2.1. Market Revenue and Forecast (2021-2032)

10.1.3. Other

10.1.3.1. Market Revenue and Forecast (2021-2032)

Chapter 11. Global MRNA Therapeutics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Application (2021-2032)

11.1.2. Market Revenue and Forecast, by Type (2021-2032)

11.1.3. Market Revenue and Forecast, by End User (2021-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Application (2021-2032)

11.1.4.2. Market Revenue and Forecast, by Type (2021-2032)

11.1.4.3. Market Revenue and Forecast, by End User (2021-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Application (2021-2032)

11.1.5.2. Market Revenue and Forecast, by Type (2021-2032)

11.1.5.3. Market Revenue and Forecast, by End User (2021-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Application (2021-2032)

11.2.2. Market Revenue and Forecast, by Type (2021-2032)

11.2.3. Market Revenue and Forecast, by End User (2021-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Application (2021-2032)

11.2.4.2. Market Revenue and Forecast, by Type (2021-2032)

11.2.4.3. Market Revenue and Forecast, by End User (2021-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Application (2021-2032)

11.2.5.2. Market Revenue and Forecast, by Type (2021-2032)

11.2.5.3. Market Revenue and Forecast, by End User (2021-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Application (2021-2032)

11.2.6.2. Market Revenue and Forecast, by Type (2021-2032)

11.2.6.3. Market Revenue and Forecast, by End User (2021-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Application (2021-2032)

11.2.7.2. Market Revenue and Forecast, by Type (2021-2032)

11.2.7.3. Market Revenue and Forecast, by End User (2021-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Application (2021-2032)

11.3.2. Market Revenue and Forecast, by Type (2021-2032)

11.3.3. Market Revenue and Forecast, by End User (2021-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Application (2021-2032)

11.3.4.2. Market Revenue and Forecast, by Type (2021-2032)

11.3.4.3. Market Revenue and Forecast, by End User (2021-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Application (2021-2032)

11.3.5.2. Market Revenue and Forecast, by Type (2021-2032)

11.3.5.3. Market Revenue and Forecast, by End User (2021-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Application (2021-2032)

11.3.6.2. Market Revenue and Forecast, by Type (2021-2032)

11.3.6.3. Market Revenue and Forecast, by End User (2021-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Application (2021-2032)

11.3.7.2. Market Revenue and Forecast, by Type (2021-2032)

11.3.7.3. Market Revenue and Forecast, by End User (2021-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Application (2021-2032)

11.4.2. Market Revenue and Forecast, by Type (2021-2032)

11.4.3. Market Revenue and Forecast, by End User (2021-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Application (2021-2032)

11.4.4.2. Market Revenue and Forecast, by Type (2021-2032)

11.4.4.3. Market Revenue and Forecast, by End User (2021-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Application (2021-2032)

11.4.5.2. Market Revenue and Forecast, by Type (2021-2032)

11.4.5.3. Market Revenue and Forecast, by End User (2021-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Application (2021-2032)

11.4.6.2. Market Revenue and Forecast, by Type (2021-2032)

11.4.6.3. Market Revenue and Forecast, by End User (2021-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Application (2021-2032)

11.4.7.2. Market Revenue and Forecast, by Type (2021-2032)

11.4.7.3. Market Revenue and Forecast, by End User (2021-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Application (2021-2032)

11.5.2. Market Revenue and Forecast, by Type (2021-2032)

11.5.3. Market Revenue and Forecast, by End User (2021-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Application (2021-2032)

11.5.4.2. Market Revenue and Forecast, by Type (2021-2032)

11.5.4.3. Market Revenue and Forecast, by End User (2021-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Application (2021-2032)

11.5.5.2. Market Revenue and Forecast, by Type (2021-2032)

11.5.5.3. Market Revenue and Forecast, by End User (2021-2032)

Chapter 12. Company Profiles

12.1. Alnylam Pharmaceuticals

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Arcturus Therapeutics

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Argos Therapeutics Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. AstraZeneca plc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. BioNTech SE

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. CRISPR Therapeutics AG

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Curevac AG

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Etherna Immunotherapies

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Ethris GMBH

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. GSK plc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample